Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research
General Research
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From TheBodyPRO.com
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO.com
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From TheBodyPRO.com
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
VIEW ALL ARTICLES
Efavirenz (Sustiva, Stocrin)
- Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort (March 20, 2013)
From HIVandHepatitis.com
- Efavirenz Tied to Neurological Birth Defects (March 8, 2013)
From MedPage Today
- Small Risk of Neurological Birth Defects Due to Efavirenz Confirmed in French Cohort (March 6, 2013)
From aidsmap.com
- Long-Term Efavirenz Linked to Worse Neurocognitive Function in U.S. CHARTER Group (March 5, 2013)
From National AIDS Treatment Advocacy Project
- Sustiva, Atripla Tied to Neurologic Toxicity (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
 Popular HIV Drug May Cause Memory Declines (October 3, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efavirenz Interaction Studies With TB Compounds Bedaquiline and Delamanid (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Efavirenz Levels Variable in Children in the CHAPAS-3 Study (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- 20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
VIEW ALL ARTICLES
Nevirapine (Viramune)
- Longer Use of Nevirapine Stops HIV in Babies (March 8, 2013)
From MedPage Today
- Nevirapine-Containing ART Does Not Reduce Combined Oral Contraceptive Effectiveness (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Lipid Profile in Children in PREDICT: Immediate Versus Deferred Nevirapine-Based ART (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Adding Nevirapine to HIV Regimen Halves Newborn Transmission Rate (June 20, 2012)
Findings from NIH network support shift in prevention guidelines.
From U.S. National Institutes of Health
On TheBodyPRO.com
- Kaletra Superior to Viramune in HIV-Positive Infants, U.S. Study Finds (November 3, 2010)
From National Institute of Allergy and Infectious Diseases
On TheBodyPRO.com
- NEJM PMTCT Studies (October 15, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Study Findings on Nevirapine Support WHO HIV Treatment Guideline Changes (October 14, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Once-Daily "Extended" Formulation of Nevirapine Holds Up Well in 48-Week Study Results (September 15, 2010)
In The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Study Shows Nevirapine a New Treatment Option for HIV-Positive Infants (September 8, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Once-Daily Extended-Release Nevirapine Works as Well as Twice-Daily Formulation (July 23, 2010)
From aidsmap.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
